Preference-based quality of life in patients with Alzheimer's disease

Alzheimer's and Dementia

Volumn 4, Issue 3, 2008, Pages 193-202

  Karlawish, Jason H ^a   Zbrozek, Art ^b   Kinosian, Bruce ^a   Gregory, Annemarie ^a   Ferguson, Allison ^a   Glick, Henry A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PFIZER INC   (United States)

Author keywords

Alzheimer's disease; Cost effectiveness analysis; EQ 5D; Health Utilities Index; Quality of life

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CAREGIVER; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DAILY LIFE ACTIVITY; DISABILITY; DISEASE SEVERITY; FEASIBILITY STUDY; FEMALE; HUMAN; HYPOTHESIS; INTROSPECTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOOD; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RELIABILITY; SCORING SYSTEM; SELF CONCEPT; VALIDATION STUDY; VALIDITY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS;

EID: 43649092627     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.11.019     Document Type: Article

References (46)

1. Mohs R.C. The Alzheimer's Disease Assessment Scale. Int Psychogeriatr 8 (1996) 195-203
2. Galasko D., Bennett D., Sano M., Ernesto C., Thomas R., Grundman M., et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 Suppl 2 (1997) S33-S39
3. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 43 (1993) 2412-2414
4. Schneider L.S., and Olin J.T. Clinical Global Impression of change: Clinical Global Impressions in Alzheimer's clinical trials. Int Psychogeriatr 8 (1996) 277-290
5. Leber P. Guidelines for the clinical evaluation of antidementia drugs: 1st Draft (1990), Food and Drug Administration, Center for Drug Evaluation and Research, Division of Neuropharmacological Drug Products, Rockville, MD 39
6. Gold M.R., Patrick D.L., Torrance G.W., Fryback D.G., Hadon D.C., Kamlet M.S., et al. Identifying and valuing outcomes. In: Gold M.R., Siegel J.E., Russel L.B., and Weinstein M.C. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, Oxford 82-134
7. Glick H.A., Doshi J.A., Sonnad S.F., and Polsky D. Assessing quality-adjusted life years: economic evaluation in clinical trials (2007), Oxford University Press, Oxford 9-87
8. Andersen C.K., Wittrup-Jensen K.U., Lolk A., Andersen K., and Kragh-Sorensen P. Ability to perform activities of daily living is the main factor affecting quality of life in patients with dementia. Health Qual Life Outcomes 2 (2004) 52
9. Neumann P.J., Hermann R.C., Kuntz K.M., Araki S.S., Duff S.B., Leon J., et al. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 52 (1999) 1138-1145
10. Neumann P.J., Kuntz K.M., Leon J., Araki S.S., Hermann R.C., Hsu M.-A., et al. Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers. Med Care 37 (1999) 27-32
11. Neumann P.J., Sandberg E.A., Araki S.S., Kuntz K.M., Feeny D., and Weinstein M.C. A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease. Med Decis Making 20 (2000) 413-422
12. Dolan P. Modeling valuations for EuroQol health states. Med Care 35 (1997) 1095-1108
13. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimer's Disease. vol 2006 (2006), National Institute for Health and Clinical Excellence, London
14. Jonsson L., Andreasen N., Kilander L., Soininen H., Waldemar G., Nygaard H., et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 20 (2006) 49-55
15. Coucill W., Bryan S., Bentham P., Buckley A., and Laight A. EQ-5D in patients with dementia. Med Care 39 (2001) 760-771
16. Ankri J., Beaufils B., Novella J.-L., Morrone I., Guillemin F., Jolly D., et al. Use of the EQ-5D among patients suffering from dementia. J Clin Epidemiol 56 (2003) 1055-1063
17. Naglie G., Tomlinson G., Tansey C., Irvine J., Ritvo P., Black S., et al. Utility-based quality of life measures in Alzheimer's disease. Qual Life Res 15 (2006) 631-643
18. Vogel A., Mortensen E.L., Hasselbalch S.G., Andersen B.B., and Waldemar G. Patient versus informant reported quality of life in the earliest phases of Alzheimer's disease. Int J Geriatr Psychiatry 21 (2006) 1132-1138
19. American Psychiatric Association. Diagnostic and statistical manual of mental disorders IV (1994), American Psychiatric Association, Washington, DC
20. Streiner D.L., and Norman G.R. Validity health measurement scales: a practical guide to their development and use (1996), Oxford University Press, Oxford 144-162
21. McKhann G., Drachman D., Folstein M., Katzman R., Price D., and Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under auspices of the Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 34 (1984) 939-944
22. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
23. Torrance G.W., Feeny D.H., Furlong W.J., Barr R.D., Zhang Y., and Wang Q. Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. Medical Care 34 (1996) 702-722
24. Teng E.L., and Chui H.C. The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry 48 (1987) 314-318
25. Lawton M.P., and Brody E.M. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9 (1969) 179-186
26. Yesavage J.A., Brink T.L., Rose T.L., Lum O., Huang V., Adey M., et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 17 (1983) 37-49
27. Logsdon R.G., Gibbons L.E., McCurry S.M., and Teri L. Quality of life in Alzheimer's disease: patient and caregiver reports. Journal of Mental Health and Aging 5 (1999) 21-32
28. Ware J.E., Kosinski M., and Keller S.D. SF-12: how to score the SF-12 physical and mental health summary scales (1995), The Health Institute, New England Medical Center, Boston
29. Smith C.A., Henderson V.W., McCleary C.A., Murdock G.A., and Buckwalter J.G. Anosognosia and Alzheimer's disease: the role of depressive symptoms in mediating impaired insight. J Clin Exp Neuropsychol 22 (2000) 437-444
30. Landis J.R., and Koch G.G. The measurement of observer agreement for categorical data. Biometrics 33 (1977) 159-174
31. Siderowf A., Ravina B., and Glick H.A. Preference-based quality-of-life in patients with Parkinson's disease. Neurology 59 (2002) 103-108
32. Ready R.E., Ott B.R., and Grace J. Insight and cognitive impairment: effects on quality-of-life reports from mild cognitive impairment and Alzheimer's disease patients. Am J Alzheimers Dis Other Demen 21 (2006) 242-248
33. Kiyak H.A., Teri L., and Borson S. Physical and functional health assessment in normal aging and in Alzheimer's disease: self-reports vs family reports. Gerontologist 34 (1994) 324-330
34. Ready R.E., Ott B.R., Grace J., and Fernandez I. The Cornell-Brown Scale for Quality of Life in dementia. Alzheimer Dis Assoc Disord 16 (2002) 109-115
35. Logsdon R.G., Gibbons L.E., McCurry S.M., and Teri L. Assessing quality of life in older adults with cognitive impairment. Psychosom Med 64 (2002) 510-519
36. Calhoun E.A., Fishman D.A., Lurain J.R., Welshman E.E., and Bennett C.L. A comparison of ovarian cancer treatments: analysis of utility assessments of ovarian cancer patients, at-risk population, general population, and physicians. Gynecol Oncol 93 (2004) 164-169
37. Epstein A.M., Hall J.A., Tognetti J., Son L.H., and Conant Jr. L. Using proxies to evaluate quality of life: can they provide valid information about patients' health status and satisfaction with medical care?. Med Care 27 (1989) S91-S98
38. Gabriel S.E., Kneeland T.S., Melton III L.J., Moncur M.M., Ettinger B., and Tosteson A.N. Health-related quality of life in economic evaluations for osteoporosis: whose values should we use?. Med Decis Making 19 (1999) 141-148
39. Prosser L.A., Kuntz K.M., Bar-Or A., and Weinstein M.C. Patient and community preferences for treatments and health states in multiple sclerosis. Mult Scler 9 (2003) 311-319
40. Sackett D.L., and Torrance G.W. The utility of different health states as perceived by the general public. J Chron Dis 31 (1978) 697-704
41. Kasckow J.W., Twamley E., Mulchahey J.J., Carroll B., Sabai M., Strakowski S.M., et al. Health-related quality of well-being in chronically hospitalized patients with schizophrenia: comparison with matched outpatients. Psychiatry Res 103 (2001) 69-78
42. Montes J.M., Ciudad A., Gascon J., and Gomez J.C. EFESO Study Group: safety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia-a naturalistic study. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 667-674
43. Patterson T.L., Kaplan R.M., Granta I., Semple S.J., Mascona S., Koch W., et al. Quality of well-being in late-life psychosis. Psychiatry Res 63 (1996) 169-181
44. Prieto L., Novick D., Sacristan J.A., Edgell E.T., and Alonso J. SOHO Study Group: a Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatr Scand Suppl 416 (2003) 24-29
45. Pyne J.M., Sullivan G., Kaplan R., and Williams D.K. Comparing the sensitivity of generic effectiveness measures with symptom improvement in persons with schizophrenia. Med Care 41 (2003) 208-217
46. van der Zanden B., Dijkgraar M., Blanken P., de Borgie C., van Ree J., and van den Brink W. Validity of the EQ-5D as a generic health outcome instrument in a heroin-dependent population. Drug Alcohol Depend 82 (2006) 111-118